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Introduction
Due to the outbreak of the COVID-19 pandemic, the first quarter of 2020 has seen levels of burden on health 
care systems which have not been seen in relation to a viral infection since the influenza pandemic of 19181-3. A
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While social distancing, testing and containment have undoubtedly led to a significant reduction in morbidity 
and loss of life, their societal impact and resulting economic upheaval are unprecedented. The extent of the 
measures taken across the globe vary significantly, and range from stringent testing and isolation to more 
lenient ‘intelligent lockdowns’, and these by-and-large reflect national and regional cultural and ethical 
differences in weighing the acceptability of limitation of personal freedoms against strain on the health care 
system and ensuing loss of life, as well as the level of preparedness to accept the consequences of a potential 
‘second wave’ in case of a delay in the development of an effective vaccine. However, differences in practice 
are probably also related to our as yet limited understanding of the natural evolution of the disease, which 
varies greatly between populations, and is probably related to a host of patient-related and environmental 
risk factors. 
The clinical features of a patient with COVID-19 range from a mild illness with slight complaints such as sore 
throat and headache, to patients who have to be admitted to hospital because of hypoxemia caused by 
pneumonia, to patients with a very severe illness who have acute hypoxemic respiratory failure and need to 
be admitted to an Intensive Care Unit3-7. In general, mortality rates are approximately 2%, but once admitted 
to hospital this rate can increase to 28%4,6,7. Risk factors for a fatal disease are older age, an increased D-
dimer and an increased SOFA score4. Until now, there is no evidence-based effective treatment options for 
COVID-19. Therefore, hypotheses need to be generated about the underlying pathophysiological mechanisms 
of a mild to very severe disease, so that new treatment strategies for these different categories of patients 
can be developed and investigated.
Thus, while we now know that higher age and a range of comorbidities (such as respiratory disorders, 
cardiovascular disease, diabetes and obesity) pose significant risks for those infected with SARS-CoV-2, little is 
known about the mechanisms behind the infrequent idiosyncratic clinical demise in otherwise healthy young 
subjects (although there may be an effect of the level of exposure), and the reasons for observed differences 
in resolution of the disease following an otherwise comparable clinical course in patients with similar risk 
factor profiles. As in other diseases, the answer to some of these questions may in time be provided by 
genotyping as well careful clinical, serological, radiological and histopathological phenotyping, which enable 
mechanistic insights into the differences in pathogenesis and underlying immunological and tissue 
regenerative response patterns. While little is known so far regarding COVID-19 histology, we will aim to 
provide a brief overview of the existing evidence for such differences in host response and outcome, and A
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generate hypotheses for divergent patterns and avenues for future research, by highlighting similarities and 
differences in histopathological appearance between COVID19 and influenza as well as previous coronavirus 
outbreaks, and by discussing predisposition through genetics and underlying disease.
Respiratory tract histopathology in influenza
The archetypical previous pandemic leading to a massive worldwide loss of life due to pneumonia and 
respiratory failure is the influenza pandemic of 1918, which killed approximately 50 million people worldwide, 
and which was caused by an RNA virus of the family orthomyxoviridae that contains a negative-sense (as 
opposed to the positive strand in coronaviruses), single-stranded, segmented RNA genome. The 
histopathology described in cases of various influenza pandemics stems mainly from autopsy cases, and 
therefore leads to bias towards severe cases. Larger case series are available for the 1918 pandemic, as well 
as limited descriptions of later pandemics and inter-pandemic cases, and only 3 autopsy cases of the more 
recent H5N1 Highly Pathogenic Avian Influenza Infection8. Nonetheless, it has become clear that while there 
is a wide range of pulmonary histological response patterns to influenza infection, which varies with both 
clinical picture and length of the disease course before death, the range appears to be similar for most 
influenza subtypes. The respiratory tract histology of influenza reflects its cellular tropism, as influenza virus 
replicates in respiratory epithelial cells throughout the respiratory tree, with non-fatal infections 
predominantly involving the upper respiratory tract and trachea, but fatal cases of influenza usually result 
from pneumonia. Coincident or secondary bacterial pneumonias are extremely common in severe influenza 
and also complicate the histopathologic appearance. As these are primarily related to outcome, we will 
restrict our commentary to the histopathological changes observed in the lower respiratory tract. Changes in 
the smaller airways include necrosis and complete loss of the epithelial layer (both ciliated and goblet cells), 
often resulting in the formation of hyaline membranes at these sites. Neutrophilic inflammation may be 
present in the lumen, and extend into surrounding alveoli. In addition, a more chronic 
lymphoplasmahistiocytic infiltrate is often seen in influenza-infected airways. The parenchyma shows 
evidence of acute injury with interstitial congestion, edema, and inflammation (predominantly neutrophilic 
with some eosinophils), as well as desquamated alveolar epithelial cells, intra-alveolar edema, intra-alveolar 
hemorrhage, fibrin, hyaline membrane formation, and sometimes necrosis of the alveolar septa (necrotizing 
alveolitis), the latter possibly resulting from frequently observed vascular changes with capillary congestion 
and thrombosis. Mitotic activity and regeneration of respiratory epithelium start after approximately 5 days A
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and the level of regeneration is possibly related to outcome. Thus, variable mitotic activity but no evidence of 
true regeneration of the epithelial layer has been seen in rapidly lethal cases. If the patient survives, 
organizing diffuse alveolar damage, increased numbers of intra-alveolar macrophages, epithelial regeneration 
(incl. type II alveolar hyperplasia), squamous metaplasia, chronic interstitial inflammation and eventually 
interstitial fibrosis may be seen. Megakaryocytes lying within the capillary bed are also commonly seen. 
Coincident bacterial pneumonias frequently occur and complicate the pathologic picture by massive 
infiltration of neutrophils into alveolar spaces. In general, most interpandemic cases seem to be associated 
with fewer changes of primary influenza virus pneumonia (such as edema), and more changes attributable to 
secondary bacterial pneumonia. 
Respiratory tract histopathology in coronavirus infection (COVID-19, SARS, MERS)
Limited data are available regarding the histopathological spectrum of COVID-19 pneumonia. Of the 41 SARS-
CoV-2-infected patients admitted in the early stages of the outbreak, six died from acute respiratory distress 
syndrome (ARDS)2, and four subsequent reports9-12 on the histological examination of the lungs of in total 
seven patients with SARS-CoV-2 indeed showed signs compatible with ARDS. These included bilateral acute 
changes with diffuse alveolar damage (DAD) with vascular congestion, intra-alveolar edema, hemorrhage, 
proteinaceous exudate, macrophages, denudation and reactive hyperplasia of pneumocytes, patchy 
inflammatory cellular infiltration, and multinucleated giant cells, but hyaline membrane formation was not 
prominent. The infiltrate consisted of lymphocytes (mostly CD4-positive), eosinophils and neutrophils. 
Hyaline thrombi were found in microvessels. We have recently also observed similar changes in COVID-19 
autopsy cases, with evidence of extensive microvascular damage and thrombotic occlusion as the foremost 
pattern of injury, resulting in intra-alveolar fibrinous exudates akin to acute fibrinous and organizing 
pneumonia (AFOP) (Fig.1). This spectrum of abnormalities is highly reminiscent of changes seen in the context 
of the chronic lung allograft rejection (CLAD) of the restrictive phenotype (restrictive allograft syndrome 
(RAS)), which we have recently described, and which is presumed to occur secondary to antibody-mediated 
endothelial damage and complement activation of humoral rejection episodes13. Such vascular changes are 
likely to play a central role in the pathogenesis of COVID-19, and may in part be attributable to dysregulation 
of the endothelial ACE2 receptor with ensuing bradykinin-dependent local lung edema14, as well as a highly 
pro-thrombotic state, which can manifest itself in the lung as well as in extra-pulmonary tissues15.  Direct A
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infection of endothelial cells may play a central role in this process16. More chronic changes included intra-
alveolar organization with fibroblastic proliferation and diffuse fibrotic thickening of alveolar walls, consisting 
of proliferating interstitial fibroblasts. In RAS, we have found this to eventually result in chronic fibrotic 
patterns of intra-alveolar fibroelastosis and non-specific interstitial pneumonia (NSIP)13. Time will tell if a 
similar progression to fibrosis will take place in a subset of survivors of severe COVID-19, and whether this is 
indeed secondary to vascular damage, primarily related to the initial epithelial infection, or a combination of 
these response patterns (Fig. 2). Apart from the prominent microvascular changes, the pathological features 
of COVID-19 thereby appear to resemble those seen in SARS and Middle Eastern respiratory syndrome 
(MERS) coronavirus infection17-19. Thus, early SARS-CoV infections were found to be typified by acute diffuse 
alveolar damage, and late stages by a combination of diffuse alveolar damage and acute fibrinous and 
organizing pneumonia. MERS-CoV infections also showed exudative diffuse alveolar damage with hyaline 
membranes, pulmonary edema, type II pneumocyte hyperplasia, (lymphocytic) interstitial pneumonia, and 
multinucleated syncytial cells. 
Bedside observations and future guidance in COVID-19  : translation from histopathology
Poor oxygenation requiring ventilation and oxygen administration in influenza as well as coronavirus infection 
is likely to be in part directly related to decreased diffusion capacity due to parenchymal destruction as well 
as increased diffusion distances due to 1) intra-alveolar aggregates of edema, fibrin, hyaline membranes, cells 
and organization, 2) widening of alveolar septa due to edema and inflammation, 3) vascular changes with 
capillary congestion and thrombosis and 4) eventually, intrabronchiolar, intra-alveolar and interstitial fibrosis. 
While regeneration and reversal of the first 3 phenomena is theoretically possible, and as in influenza may be 
related to the regenerative capacity of the host, it may occur at lower rates in SARS-CoV-2 infection as 
compared to other viral pneumonias. Intra-alveolar and interstitial fibrosis, however, are most likely 
irreversible, and may have contributed to the remarkably high number of patients who cannot be weaned off 
ventilation in the current COVID-19 outbreak. Also, in survivors we may eventually see a significant number of 
cases with irreversible fibrotic lung damage and limited pulmonary function, which has previously been 
termed COLD (‘Corona Obstructive Lung Disease’). To which extent this term truly reflects the underlying 
physiology remains to be seen, as the interstitial fibrotic changes which have thus far been observed are likely 
to also lead to a restrictive lung defect as well as permanently decreased diffusion capacity, and are thus 
more akin to other types of (idiopathic) interstitial lung fibrosis, such as forms of the abovementioned intra-A
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alveolar fibroelastosis and fibrotic NSIP, and could therefore perhaps be more accurately termed Corona-
Associated Lung Disease (‘CALD’). This will require multi-center studies which correlate histopathological 
findings with clinical and radiological data. 
Genetics in COVID-19
A sudden demise in COVID-19 may be related to a cytokine storm, which can be an important component of 
ARDS, multiple organ failure and eventual death in SARS-CoV-2, SARS-CoV and MERS-CoV infections9, and is 
reflected by the release of large amounts of pro-inflammatory cytokines (incl. IFN-α, IFN-γ, IL-1β, IL-6, IL-12, 
IL-18, IL-33, TNF-α, TGFβ) and chemokines (incl. CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10, etc.) by immune 
effector cells12. In the case of influenza, hypercytokinemia has been found to be correlated with the 
occurrence of hemophagocytosis, which was observed to a varying degree in cases of influenza pneumonia. 
Whether a similar mechanism is at play in COVID-19 has yet to be resolved from hematological, 
immunological and histopathological assessment. In general, however, an overly active inflammatory 
response is likely to contribute to tissue damage and systemic effects in COVID-19, and this may be related to 
genetically determined differences in inherent individual immune response mechanisms as well as being 
subject to the influence of concomitant diseases. Thus, previous research shows that numerous HLA 
polymorphisms correlate with the susceptibility of SARS-CoV and MERS-CoV infection, and gene 
polymorphisms of MBL (mannose-binding lectin) associated with antigen presentation have also been linked 
to the risk of SARS-CoV infection20. Also, the single-nucleotide polymorphism rs12252-C/C in the gene IFITM3 
(which encodes interferon-induced transmembrane protein 3) has been demonstrated to be a risk factor for 
severe influenza, and has also been found in a patient with COVID-1921. Genetics may also play a role through 
polymorphisms of genes which encode for 1) proteins that are exploited by SARS-CoV-2, such as the highly 
conserved Angiotensin Converting Enzyme 2 (ACE2), which, as was also the case for SARS-CoV, it uses for 
docking and cellular entry in respiratory cells, or 2) proteins which provide protection against the effects of 
the virus (such as surfactant proteins, but also ACE2 itself)22. Genetic association studies are currently ongoing 
to unravel such hypotheses, and have found correlations between ACE2 variants and COVID-19 
susceptibility23,24. Interestingly, as an X-linked phenotype, the effectiveness of interaction-booster and 
interaction-inhibitor variants of ACE2 can be more definite in males than females, and could contribute 
towards a higher mortality rate in males, accounting for up to ∼70% of death caused by SARS-CoV2, SARS-
CoV or MERS-CoV25, in addition to a likely higher rate of risk factors (e.g. smoking) and a possibly different A
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immune response in males. Other entry mechanisms may also play a role, such as transmembrane protease 
serine 2 (TMPRSS2), and TMPRSS2 variants and expression have indeed been linked to  differences in COVID-
19 severity26. Susceptibility to the development of post-COVID-19 pulmonary fibrosis could also have a 
genetic component, as variants in numerous genes or their promotors (such as MUC5B and TERT) have been 
found to predispose to lung fibrosis, both in the context of idiopathic pulmonary fibrosis and in interstitial 
fibrosis related to hypersensitivity pneumonitis and collagen vascular disease27-30.
Underlying disease in COVID-19
ACE2 could also be pivotal in the particular susceptibility of diabetic and hypertensive patients for fulminant 
COVID-19. While diabetic patients are known to have impaired immune responses, diabetes (as well as 
hypertension) are associated with activation of the renin-angiotensin system in different tissues, and are 
often treated with ACE inhibitors and angiotensin receptor blockers (ARBs), which can lead to increased 
expression of ACE2, thereby potentially facilitating viral uptake. Similarly, in MERS, dipeptidyl peptidase 4 
(DPP4) inhibition in diabetic patients could have potentiated entry of the virus MERS-CoV, which uses DPP4 as 
its receptor31. Discontinuation of ARBs would be premature at this stage, however, as ACE2 is also likely to 
protect against the effects of SARS-CoV-2 infection32-34. Obesity is a further important risk factor for mortality 
following COVID-19, and may be related to the fact that the majority of those with obesity also have impaired 
lung function and underlying diseases, such as chronic lung disease, including asthma, cardiac problems, or 
diabetes, which are risk factors on their own for survival following ICU admission, but also for mortality in 
COVID-19, in which multi-organ failure is a common occurrence and good baseline cardiorespiratory function 
of crucial benefit35. 
Conclusion
In summary, despite the relatively recent outbreak of the COVID-19 pandemic, an impressive body of 
preliminary evidence has already been accumulated which points to a remarkable heterogeneity of disease 
patterns from a clinical, radiological, and histopathological point of view. This has identified broad risk groups, 
but sometimes also idiosyncratic responses of individual patients in these groups are seen. These may be in 
part related to underlying genetic variations, which contribute to differences in outcome in the short term, 
but possibly also affect the extent of residual pulmonary damage following survival of the acute phase of the 
disease. More research is required to expand and confirm these associations, in order to enable adequate 
prevention, prognosis, follow-up and possibly treatment in at-risk populations. A
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FIGURE 1: Spectrum of tissue response patterns in COVID-19 pneumonia.
In the lung tissue of patients who died of respiratory failure due to COVID19 pneumonia, there can be  
evidence of epithelial infection with cytopathic effects of pneumocytes (A, box); denudation of bronchiolar 
epithelium (B), and evidence of diffuse alveolar damage (DAD) with hyaline membrane formation with 
organization (C). Observed vascular changes include extensive bilateral and diffuse (micro)vascular damage 
and its sequelae, with arterial thrombosis with organization (D), microvascular fibrinoid change with hyaline 
thrombi (E, fibrin-Lendrum (MSB) stain, arrows) and edema (**), and extensive intra-alveolar fibrinous 
aggregates (F) with an acute fibrinous and organizing pneumonia (AFOP) pattern (F, *). Fibrotic changes vary 
in appearance and include organizing pneumonia with progression to fibrosis (G), intra-alveolar fibro-elastosis 
(Elastic-van Gieson, H) and fibrotic non-specific interstitial pneumonia (F-NSIP; I). There is often relatively 
sparse interstitial chronic inflammation with an acute interstitial pneumonia pattern (AIP; J), foci of 
lymphocytic vasculitis (K) and acute inflammation, especially in relation to areas of necrosis and possible 
secondary infection (L). 
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FIGURE 2: Co-occurrence and potential progression of tissue response patterns in COVID-19 pneumonia.
DAD=diffuse alveolar damage; OP=organizing pneumonia; AFOP=acute fibrinous and organizing pneumonia; 
F-NSIP=fibrotic non-specific interstitial pneumonia; AIP=acute interstitial pneumonia
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